ARCT vs ENTA: stock comparison and AI forecast
Arcturus Therapeutics Holdings Inc. (ARCT) and Enanta Pharmaceuticals Inc (ENTA) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ARCT Arcturus Therapeutics Holdings Inc.
- Price
- $9.36 +5.2% · 6M
- Market Cap
- $266M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
ENTA Enanta Pharmaceuticals Inc
- Price
- $10.08 -33.2% · 6M
- Market Cap
- $294M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- ENTA is 1.1 times larger than ARCT by market capitalization ($294M against $266M).
- Over the last six months ARCT returned +5.2% and ENTA -33.2%.
- ENTA turns -96.9% of its revenue into net income, against -342.2% for ARCT.
- ENTA carries 1.94 times debt per unit of equity, against 0.28 times for ARCT.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ARCT | ENTA |
|---|---|---|
| Market Cap | $266M | $294M |
| P/B Ratio | 1.58x | 2.90x |
| EPS | $-3.01 | $-1.55 |
| Book Value/Share | $5.94 | $3.47 |
| Revenue/Share | $0.90 | $2.24 |
| FCF/Share | $-2.20 | $-1.27 |
Profitability & Margins
| Metric | ARCT | ENTA |
|---|---|---|
| ROE | -51.7% | -62.6% |
| ROA | -40.5% | -21.3% |
| ROIC | -50.8% | -24.2% |
| Operating Margin | -372.5% | -90.0% |
| Net Margin | -342.2% | -96.9% |
| EBT Margin | -349.9% | -96.7% |
| Tax Rate | 0.0% | -0.2% |
Financial Health
| Metric | ARCT | ENTA |
|---|---|---|
| Current Ratio | 6.68x | 3.76x |
| D/E Ratio | 0.28x | 1.94x |
| Financial Leverage | 1.28x | 2.94x |
| Interest Coverage | 4.4x | -5.2x |
| Working Capital | $161M | $149M |
Cash Flow
| Metric | ARCT | ENTA |
|---|---|---|
| Operating Cash Flow | -$62M | -$35M |
| Free Cash Flow | -$62M | -$37M |
| Capital Spending | $40K | -$2M |
| FCF/Sales | -244.9% | -56.6% |
| CapEx/Sales | 0.1% | 2.5% |
Operational Efficiency
| Metric | ARCT | ENTA |
|---|---|---|
| Asset Turnover | 0.12x | 0.22x |
| Receivables Turnover | 20.4x | 10.0x |
| Fixed Assets Turnover | 5.3x | 2.0x |
| Days Sales Outstanding | 18 days | 37 days |
Income Statement
| Metric | ARCT | ENTA |
|---|---|---|
| Total Revenue | $25M | $65M |
| Operating Income | -$95M | -$59M |
| Net Income | -$87M | -$63M |
| R&D Expense | $81M | $86M |
Dividend & Shareholder Information
| Metric | ARCT | ENTA |
|---|---|---|
| Shares Outstanding | 28M | 29M |
ARCT vs ENTA: stock comparison and AI forecast
Which is bigger, ARCT or ENTA?
ENTA is 1.1 times larger than ARCT by market capitalization ($294M against $266M).
Which stock performed better over the last six months, ARCT or ENTA?
Over the last six months ARCT returned +5.2% and ENTA -33.2%.
Which one does Intratio's AI model rank higher, ARCT or ENTA?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.